ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2005
Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00551161 (An Open-label Exploratory Study With Memantine), which is not on this map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 201 citations in OpenAlex.
- UsingInternational journal of molecular sciences · 2025Pooled it
- Imaging the Pathophysiology of Essential Tremor-A Systematic Review.Frontiers in neurology · 2021Pooled it
- ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.PloS one · 2018Trial
- Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.AJNR. American journal of neuroradiology · 2012Trial
- Trial
- Neurometabolic Signatures of Alexithymia and Visuospatial Abilities in Parkinson's Disease: An ExploratoryJournal of clinical medicine · 2026Article
- The Impact of Motor Symptom Asymmetry on the Relationship Between Non-Motor Manifestations and Neurometabolic Profiles in Parkinson's Disease.International journal of molecular sciences · 2026Article
- Thalamic metabolite changes after subthalamic nucleus deep brain stimulation in Parkinson's disease: an exploratory magnetic resonance spectroscopy study.Frontiers in neurology · 2025Article
- Sepsis-driven metabolic reprogramming shapes cancer immunotherapy efficacy, metastatic potential, and drug sensitivity.Frontiers in immunology · 2025Review
- Metabolic alterations in patients with essential tremor before and after deep brain stimulation: keys to understanding tremor using magnetic resonance spectroscopy.Frontiers in neurology · 2025Article
- Accuracy of Proton Magnetic Resonance Spectroscopy in Distinguishing Neoplastic From Non-neoplastic Brain Lesions.Cureus · 2023Article
- Early metabolic alterations in the normal‑appearing grey and white matter of patients with clinically isolated syndrome suggestive of multiple sclerosis: A proton MR spectroscopic study.Experimental and therapeutic medicine · 2023Article
- Reduced GABA concentration in patients with white matter hyperintensities.Frontiers in neuroscience · 2023Article
- Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury.IEEE reviews in biomedical engineering · 2023Review
- ClinicalNeuroradiology · 2022Review
- Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease.Brain communications · 2022Article
- Apparent diffusion coefficient histogram analysis for differentiating solid ovarian tumors.Frontiers in oncology · 2022Article
- Article
- Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis.Brain sciences · 2021Review
- Lipid-suppressed and tissue-fraction corrected metabolic distributions in human central brain structures using 2DBrain and behavior · 2020Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anatomic and functional neuroimaging with magnetic resonance imaging (MRI) includes the technology more widely known as magnetic resonance spectroscopy (MRS). Now a routine automated "add-on" to all clinical magnetic resonance scanners, MRS, which assays regional neurochemical health and disease, is therefore the most accessible diagnostic tool for clinical management of neurometabolic disorders. Furthermore, the noninvasive nature of this technique makes it an ideal tool for therapeutic monitoring of disease and neurotherapeutic decision making. Among the more than 100 brain disorders that fall within this broad category, MRS contributes decisively to clinical decision making in a smaller but growing number. In this review, we will cover how MRS provides therapeutic impact in brain tumors, metabolic disorders such as adrenoleukodystrophy and Canavan's disease, Alzheimer's disease, hypoxia, secondary to trauma or ischemia, human immunodeficiency virus dementia and lesions, as well as systemic disease such as hepatic and renal failure. Together, these eight indications for MRS apply to a majority of all cases seen. This review, which examines the role of MRS in enhancing routine neurological practice and treatment concludes: 1) there is added value from MRS where MRI is positive; 2) there is unique decision-making information in MRS when MRI is negative; and 3) MRS usefully informs decision making in neurotherapeutics. Additional efficacy studies could extend the range of this capability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.